MicroPort® EP’s PathBuilder™ Steerable Introducer Wins Approval from National Medical Products Administration of China (NMPA)


The PathBuilder™ Steerable Introducer is comprised of an introducer, a dilator and a guide wire. It is a specialized device for use in the radiofrequency ablation procedure on the patients suffering cardiac arrhythmia. With a vascular access through the femoral vein, the PathBuilder™ Steerable Introducer introduces an ablation catheter or a mapping catheter to each cardiac chamber, including the left atrium using the atrial transseptal puncture procedure.

Previously, the PathBuilder™ Transseptal Introducer independently developed by MicroPort® EP had already been approved by NMPA to launch in China. The NMPA approval for PathBuilder™ Steerable Introducer is set to help MicroPort® EP provide the doctors and patients with better introducer options in the field of complex cardiac arrhythmia. In addition, the integrated electrophysiological solutions of MicroPort® EP, which combine active devices with passive devices and devices with equipment, will be further improved to benefit more Chinese cardiac arrhythmia patients.
MicroPort® CRM Announces First Implants of Eno™ and Teo™, World’s Smallest 1.5T & 3T MRI Conditional Pacemakers

MicroPort® CRM (a business unit of MicroPort Scientific Corporation), is pleased to announce the first implants of its new pacemaker families Eno™ and Teo™. The first worldwide Eno™ implant took place in Clinique La Source, Lausanne, Switzerland. The first Teo™ implants were performed by Dr. Schouwink at Katharinen-Hospital Unna, Germany.

All models of these new pacemaker families feature AutoMRI™ technology, allowing patients implanted with compatible leads to undergo MRI (Magnetic Resonance Imaging) scans in either 1.5 Tesla or 3 Tesla machines. AutoMRI™ automatically switches in and out of MRI mode upon detection of the MR field, ensuring appropriate pacemaker operation during the scan and allowing patients to benefit from optimal pacing settings right up to and just after the scan.
Firehawk® and Rega® Family Implantable Pacemakers Make the List of Health China (2018) • Top 10 Medical Devices

The Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk"™) and Rega® Family Implantable Pacemakers, both of which are products of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort"™), made the list of Health China (2018) • Top 10 Medical Devices.

The revolutionary third-generation drug-eluting stent Firehawk® is the result of eight years of research and development of MicroPort®, and it is a successfully commercialized drug-eluting stent featuring strut in-groove coating and precision target drug-releasing patent technology. Firehawk® adopts unique abluminal laser cut grooves coating design and target-eluting technology, combining the merits of the bare metal stent and drug-eluting stent, which allows Firehawk® to achieve the same clinical efficacy with significantly lower drug loading. In September 2018, the results of the Firehawk® TARGET AC European trial were published on the website of the world leading medical journal the Lancet. This is the first time that clinical data from a China manufactured drug eluting stent has been published in the Lancet since its first publication nearly 200 years ago.

The Rega® Family Implantable Pacemakers consist of three series and eight models of products, featuring the unique sleep apnea screening and the advanced SafeR™ physiological pacing therapy. Measuring only 8 cubic centimeters, the products are about 70% of the imported pacemakers in size and more suitable for the relatively thin physique of the Chinese patients. The service life of the products spans 10 to 12 years, while the prices are only 70% to 80% of those of the imported products. The inception of the Rega® Family Implantable Pacemakers ended the dominance of the imported products in the Chinese pacemaker market in the previous years. It also kicks off the new quest where China’s high-end medical devices, such as the pacemakers, will be manufactured domestically on an industrial scale, accelerating the import substitution.
Three Subsidiaries of MicroPort® Awarded the Title of 2018 Shanghai Municipality Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprise

The Shanghai Municipal Commission of Economy and Informatization made public the list of 2018 Shanghai Municipality Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprises on February 12. A total of three subsidiary companies of “MicroPort®, which MicroPort® EP, Shanghai MicroPort Endovascular MedTech Co., Ltd. (“MicroPort® Endovascular”), and MicroPort NeuroTech (Shanghai) Co., Ltd. (“MicroPort® NeuroTech”), are included in the list, making the first-time mention for MicroPort® NeuroTech as well as the second time for MicroPort® EP and MicroPort® Endovascular.

MicroPort® EP was founded in 2010 and is dedicated to the R&D, production, marketing of various kinds of medical devices and equipment that are related to the interventional diagnosis and treatment in cardiac electrophysiology, including ablation catheters, diagnosis catheters, and 3D EP navigation systems. MicroPort® Endovascular was established in 2012 and produces mainly aortic stent-graft systems, stent-graft systems in surgical operation, and big balloons and peripheral vascular stents. MicroPort® NeuroTech was founded in 2012 and is committed to the R&D, manufacturing, marketing, and technical support of the medical devices that treat the central nervous system diseases. The products of the three companies are widely used at Chinese top-tier hospitals and exported to many foreign countries and regions. Previously, they had won the titles of Shanghai Municipality Science and Technology Young Giant Enterprise, Shanghai Municipality High and New-Tech Enterprise, and Shanghai Municipality Patent Work Pilot Enterprise for several times.
MicroPort® Orthopedics and School of Medical Instrument and Food Engineering of University of Shanghai for Science and Technology Held Agreement Signing and Inauguration Ceremony for Mutual Cooperation

The MicroPort® Orthopedics Group - School of Medical Instrument and Food Engineering of University of Shanghai for Science and Technology ("the School") Excellent Engineering Education Agreement Signing and Inauguration Ceremony for Mutual Cooperation was held on the MicroPort® Suzhou Campus. MicroPort® Orthopedics China President Mr. Robin Weng and Dean of the School Mr. Baolin Liu signed the cooperation agreement on behalf of both parties respectively, and inaugurated the Medical Device United Innovation and Student Practice Base.

The mutual cooperation was jointly initiated by the three subsidiary companies of MicroPort® Orthopedics: Suzhou MicroPort® Orthopedic Medical Instrument Co., Ltd., Suzhou MicroPort® OrthoRecon Co., Ltd., and Suzhou MicroPort® Spine & Trauma Co., Ltd., which was actively echoed by the School. Suzhou Industrial Park High-end Manufacturing and International Trade District ("the District") Administrative Committee Deputy Director Mr. Hong Meng, Head of Industry Department Ms. Zhen Zhao, and Deputy Head of Workplace Safety Department Mr. Dawei Cao attended the ceremony. Mr. Robin Weng, Mr. Hong Meng, and Mr. Baolin Liu delivered their speeches and sent congratulations to the mutual cooperation.

Mr. Hong Meng said, "The cooperation is a union between an industry-leading company and a characteristic scientific research institute, which forms a key link to build the 5-in-1 innovation system covering government, industry, university, researcher and user."
For more information, please contact:

**Martin Sun**  
Chief Financial Officer  
MicroPort Scientific Corporation  
**Tel:** (86)(21) 38954600  
**Email:** ir@microport.com

**Leanne Li**  
Board Secretary & VP of Corporate General Affairs  
MicroPort Scientific Corporation  
**Tel:** (86)(21) 38954600  
**Email:** ir@microport.com